{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:59:26Z","timestamp":1791932366824,"version":"4.3.4"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The unprecedented 2013-2016 West Africa Ebola outbreak accelerated several medical countermeasures (MCMs) against Ebola virus disease (EVD). Several investigational products (IPs) were used throughout the outbreak but were not conclusive for efficacy results. Only the Randomized Controlled Trial (RCT) on ZMapp was promising but inconclusive. More recently, during the second-largest Ebola outbreak in North Kivu and Ituri provinces, Democratic Republic of the Congo (DRC), four IPs, including one small molecule (Remdesivir), two monoclonal antibody (mAb) cocktails (ZMapp and REGN-EB3) and a single mAb (mAb114), were evaluated in an RCT, the Pamoja Tulinde Maisha (PALM) study. Two products (REGN-EB3 and mAb114) demonstrated efficacy as compared to the control arm, ZMapp. There were remarkably few side effects recorded in the trial. The FDA approved both medications in this scientifically sound study, marking a watershed moment in the field of EVD therapy. These products can be produced relatively inexpensively and can be stockpiled. The administration of mAbs in EVD patients appears to be safe and effective, while several critical knowledge gaps remain; the impact of early administration of Ebola-specific mAbs on developing a robust immune response for future Ebola virus exposure is unknown. The viral mutation escape, leading to resistance, presents a potential limitation for single mAb therapy; further improvements need to be explored. Understanding the contribution of Fc-mediated antibody functions such as antibody-dependent cellular cytotoxicity (ADCC) of those approved mAbs is still critical. The potential merit of combination therapy and post-exposure prophylaxis (PEP) need to be demonstrated. Furthermore, the PALM trial has accounted for 30% of mortality despite the administration of specific treatments. The putative role of EBOV soluble Glycoprotein (sGP) as a decoy to the immune system, the virus persistence, and relapses might be investigated for treatment failure. The development of pan-filovirus or pan-species mAbs remains essential for protection. The interaction between FDA-approved mAbs and vaccines remains unclear and needs to be investigated. In this review, we summarize the efficacy and safety results of the PALM study and review current research questions for the further development of mAbs in pre-exposure or emergency post-exposure use.<\/jats:p>","DOI":"10.3389\/fimmu.2021.721328","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T17:48:49Z","timestamp":1630691329000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":72,"title":["Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection"],"prefix":"10.3389","volume":"12","author":[{"given":"Olivier","family":"Tshiani Mbaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Mukumbayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabue","family":"Mulangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"key":"B1","first-page":"245","article-title":"The Epidemic of Ebola Haemorrhagic Fever in Sudan and Zaire, 1976: Introductory Note","volume":"56","author":"Bres","year":"1978","journal-title":"Bull World Health Organ"},{"key":"B2","article-title":"Ebola Haemorrhagic Fever in Zaire, 1976. Report of an International Commission","volume":"56","author":"Burke","year":"1978","journal-title":"Bull World Health Organ"},{"key":"B3","article-title":"Ebola Haemorragic Fever in Sudan, 1976","volume":"56","author":"Deng","year":"1978","journal-title":"Bull World Health Organ"},{"key":"B4","unstructured":"History of Ebola Virus Disease (EVD) Outbreaks Error Processing SSI File2021"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33132-5","article-title":"Ebola Virus Disease","volume":"393","author":"Malvy","year":"2019","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B1400222","article-title":"Forty Years of the War Against Ebola","volume":"15","author":"Zhang","year":"2014","journal-title":"J Zhejiang Univ Sci B"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2217\/imt.13.124","article-title":"An Update on the Use of Antibodies Against the Filoviruses","volume":"5","author":"Saphire","year":"2013","journal-title":"Immunotherapy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1086\/514298","article-title":"Treatment of Ebola Hemorrhagic Fever With Blood Transfusions From Convalescent Patients","volume":"179","author":"Mupapa","year":"1999","journal-title":"J Infect Dis"},{"key":"B9","unstructured":"Potential Ebola Therapies and Vaccines2014"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604330","article-title":"A Randomized, Controlled Trial of ZMapp for Ebola Virus","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"B11","unstructured":"Ebola Virus Disease | WHO | Regional Office for Africa2021"},{"key":"B12","unstructured":"2021"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s13337-020-00619-6","article-title":"Piperine, an Alkaloid of Black Pepper Seeds can Effectively Inhibit the Antiviral Enzymes of Dengue and Ebola Viruses, an in Silico Molecular Docking Study","volume":"31","author":"Nag","year":"2020","journal-title":"Virus Dis [Internet]"},{"key":"B14","unstructured":"2021"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910993","article-title":"A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"key":"B16","first-page":"1","article-title":"Notes for the Record: Consultation on Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) for Ebola Virus Disease (EVD)","volume":"1","author":"Davey","year":"2018","journal-title":"World Heal Organ"},{"key":"B17","unstructured":"FDA Approves First Treatment for Ebola Virus2020"},{"key":"B18","unstructured":"FDA Approves Treatment for Ebola Virus2021"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30036-4","article-title":"Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Therapeutic Monoclonal Antibody Mab114 Targeting Ebola Virus Glycoprotein (VRC 608): An Open-Label Phase 1 Study","volume":"393","author":"Gaudinski","year":"2019","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy285","article-title":"Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates","volume":"218","author":"Pascal","year":"2018","journal-title":"J Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.01.015","article-title":"Immunotherapeutic Strategies to Target Vulnerabilities in the Ebolavirus Glycoprotein","volume":"54","author":"Misasi","year":"2021","journal-title":"Immun [Internet]"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30397-9","article-title":"Safety, Pharmacokinetics, and Immunogenicity of a Co-Formulated Cocktail of Three Human Monoclonal Antibodies Targeting Ebola Virus Glycoprotein in Healthy Adults: A Randomised, First-in-Human Phase 1 Study","volume":"18","author":"Sivapalasingam","year":"2018","journal-title":"Lancet Infect Dis [Internet]"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5224","article-title":"Protective Monotherapy Against Lethal Ebola Virus Infection by a Potently Neutralizing Antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science (80-)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 Antibodies Prevent and Treat SARS-CoV-2 Infection in Rhesus Macaques and Hamsters","volume":"2402","author":"Baum","year":"2020","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.109002108","article-title":"Immunoglobulin Domain Crossover as a Generic Approach for the Production of Bispeci Fi C IgG Antibodies","volume":"108","author":"Schaefer","year":"2011","journal-title":"Med Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymthe.2019.03.002","article-title":"mRNA : A Novel Avenue to Antibody Therapy","volume":"27","author":"Schlake","year":"2019","journal-title":"Mol Ther [Internet]"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0030009","article-title":"Neutralizing Antibody Fails to Impact the Course of Ebola Virus Infection in Monkeys","volume":"3","author":"Oswald","year":"2007","journal-title":"PLoS Pathog"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30118-5","article-title":"Medical Countermeasures During the 2018 Ebola Virus Disease Outbreak in the North Kivu and Ituri Provinces of the Democratic Republic of the Congo: A Rapid Genomic Assessment","volume":"19","author":"Mbala-Kingebeni","year":"2019","journal-title":"Lancet Infect Dis [Internet]"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.002","article-title":"A Human Bi-Specific Antibody Against Zika Virus With High Therapeutic Potential","volume":"171","author":"Wang","year":"2017","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.22.427567","article-title":"Bispecific Antibody Neutralizes Circulating SARS-CoV-2 Variants, Prevents Escape and Protects Mice From Disease 2 3","author":"De Gasparo","year":"2021","journal-title":"bioRxiv [Internet]"},{"key":"B31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ymeth.2018.11.008","article-title":"Engineering Therapeutic Bispecific Antibodies Using CrossMab Technology","volume":"154","author":"Klein","year":"2019","journal-title":"Methods [Internet]"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/srep19193","article-title":"Bispecific Antibody Affords Complete Post-Exposure Protection of Mice From Both Ebola (Zaire) and Sudan Viruses","volume":"6","author":"Frei","year":"2016","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.aag3267","article-title":"A \u201cTrojan Horse\u201d Bispecific-Antibody Strategy for Broad Protection Against Ebolaviruses","volume":"354","author":"Wec","year":"2016","journal-title":"Science (80-)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/JVI.00652-17","article-title":"Novel Cross-Reactive Monoclonal Antibodies Against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model","volume":"91","author":"Duehr","year":"2017","journal-title":"J Virol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12567","article-title":"Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin Transl Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep45552","article-title":"Antibody-Dependent-Cellular-Cytotoxicity-Inducing Antibodies Significantly Affect the Post-Exposure Treatment of Ebola Virus Infection","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M009483200","article-title":"High Resolution Mapping of the Binding Site on Human IgG1 for Fc\u03b3ri, Fc\u03b3rii, Fc\u03b3riii, and FcRn and Design of IgG1 Variants With Improved Binding to the Fc\u03b3r","volume":"276","author":"Shields","year":"2001","journal-title":"J Biol Chem"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.01296","article-title":"Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life","volume":"10","author":"Saunders","year":"2019","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nat [Internet]"},{"key":"B40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1586\/erv.10.152","article-title":"Progress in Filovirus Vaccine Development: Evaluating the Potential for Clinical Use","volume":"10","author":"Falzarano","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"B41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.chom.2018.12.005","article-title":"A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates","volume":"25","author":"Bornholdt","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nature07082","article-title":"Structure of the Ebola Virus Glycoprotein Bound to an Antibody From a Human Survivor | Stanford Synchrotron Radiation Lightsource","volume":"454","author":"Lee","year":"2008","journal-title":"Nat [Internet]"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.10.5762","article-title":"Processing of the Ebola Virus Glycoprotein by the Proprotein Convertase Furin","volume":"95","author":"Volchkov","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.8.3602","article-title":"The Virion Glycoproteins of Ebola Viruses are Encoded in Two Reading Frames and are Expressed Through Transcriptional Editing","volume":"93","author":"Sanchez","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1995.0052","article-title":"GP mRNA of Ebola Virus Is Edited by the Ebola Virus Polymerase and by T7 and Vaccinia Virus Polymerases1","volume":"214","author":"Volchkov","year":"1995","journal-title":"Virology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.16.10442-10450.2005","article-title":"Effects of Ebola Virus Glycoproteins on Endothelial Cell Activation and Barrier Function","volume":"79","author":"Wahl-Jensen","year":"2005","journal-title":"J Virol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.bbrc.2004.08.148","article-title":"Disulfide Bond Assignment of the Ebola Virus Secreted Glycoprotein SGP","volume":"323","author":"Barrientos","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir321","article-title":"Genomic RNA Editing and its Impact on Ebola Virus Adaptation During Serial Passages in Cell Culture and Infection of Guinea Pigs","volume":"204","author":"Volchkova","year":"2011","journal-title":"J Infect Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/vim.2014.0068","article-title":"The Multiple Roles of sGP in Ebola Pathogenesis","volume":"28","author":"De La Vega","year":"2015","journal-title":"Viral Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1086\/514280","article-title":"Recombinant Human Monoclonal Antibodies Against Ebola Virus","volume":"179","author":"Maruyama","year":"1999","journal-title":"JID"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.7.6024-6030.1999","article-title":"Ebola Virus Can Be Effectively Neutralized by Antibody Produced in Natural Human Infection","volume":"73","author":"Maruyama","year":"1999","journal-title":"J Virol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.3.1576-1580.2001","article-title":"Ebola Virus Glycoprotein: Proteolytic Processing, Acylation, Cell Tropism, and Detection of Neutralizing Antibodies","volume":"75","author":"Ito","year":"2001","journal-title":"J Virol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.5.2324-2330.2001","article-title":"Infectivity-Enhancing Antibodies to Ebola Virus Glycoprotein","volume":"75","author":"Takada","year":"2001","journal-title":"J Virol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jviromet.2007.02.004","article-title":"Production and Characterization of Monoclonal Antibodies Against Different Epitopes of Ebola Virus Antigens","volume":"143","author":"Shahhosseini","year":"2007","journal-title":"J Virol Methods"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02098-06","article-title":"Influences of Glycosylation on Antigenicity, Immunogenicity, and Protective Efficacy of Ebola Virus GP DNA Vaccines","volume":"81","author":"Dowling","year":"2007","journal-title":"J Virol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir295","article-title":"Impact of Ebola Mucin-Like Domain on Antiglycoprotein Antibody Responses Induced by Ebola Virus-Like Particles","volume":"204","author":"Martinez","year":"2011","journal-title":"J Infect Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05549-11","article-title":"Structure of an Antibody in Complex With Its Mucin Domain Linear Epitope That Is Protective Against Ebola Virus","volume":"86","author":"Olal","year":"2012","journal-title":"J Virol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.08.008","article-title":"Characterization of Zaire Ebolavirus Glycoprotein-Specific Monoclonal Antibodies","volume":"141","author":"Qiu","year":"2011","journal-title":"Clin Immunol [Internet]"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5458.1664","article-title":"Epitopes Involved in Antibody-Mediated Protection From Ebola Virus","volume":"287","author":"Wilson","year":"2000","journal-title":"Science (80-)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1001098","article-title":"Steric Shielding of Surface Epitopes and Impaired Immune Recognition Induced by the Ebola Virus Glycoprotein","volume":"6","author":"Francica","year":"2010","journal-title":"PLoS Pathog"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/ni1519","article-title":"Immunopathology of Highly Virulent Pathogens: Insights From Ebola Virus","volume":"8","author":"Zampieri","year":"2007","journal-title":"Nat Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix584","article-title":"Ebola Virus Neutralizing Antibodies Detectable in Survivors of Theyambuku, Zaire Outbreak 40 Years After Infection","volume":"217","author":"Rimoin","year":"2018","journal-title":"J Infect Dis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1086\/514318","article-title":"Clinical, Virologic, and Immunologic Follow-Up of Convalescent Ebola Hemorrhagic Fever Patients and Their Household Contacts, Kikwit, Democratic Republic of the Congo","volume":"179","author":"Rowe","year":"1999","journal-title":"J Infect Dis"},{"key":"B64","doi-asserted-by":"crossref","DOI":"10.1038\/s41564-019-0392-y","article-title":"Antibody Responses to Viral Infections: A Structural Perspective Across Three Different Enveloped Viruses","volume":"4","author":"Murin","year":"2019","journal-title":"Nat Microbiol"},{"key":"B65","unstructured":"First FDA-Approved Vaccine for the Prevention of Ebola Virus Disease, Marking a Critical Milestone in Public Health Preparedness and Response2021"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and Effectiveness of an rVSV-Vectored Vaccine in Preventing Ebola Virus Disease: Final Results From the Guinea Ring Vaccination, Open-Label, Cluster-Randomised Trial (Ebola \u00c7a Suffit)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"B67","article-title":"Preliminary Results on the Efficacy of rVSV-ZEBOV-GP Ebola Vaccine Using the Ring Vaccination Strategy in the Control of an Ebola Outbreak in the Democratic Republic of the Congo: An Example of Integration of Research Into Epidemic Response","year":""},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-17489-7","article-title":"Long-Lasting Severe Immune Dysfunction in Ebola Virus Disease Survivors","volume":"11","author":"Wiedemann","year":"2020","journal-title":"Nat Commun [Internet]"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy377","article-title":"Fully Human Immunoglobulin G From Transchromosomic Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate","volume":"218","author":"Luke","year":"2018","journal-title":"J Infect Dis"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-17446-4","article-title":"Prior Vaccination With rVSV-ZEBOV Does Not Interfere With But Improves Efficacy of Postexposure Antibody Treatment","volume":"11","author":"Cross","year":"2020","journal-title":"Nat Commun [Internet]"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2012.04.003","article-title":"Ebolavirus Vaccines for Humans and Apes","volume":"2","author":"Fausther-Bovendo","year":"2012","journal-title":"Curr Opin Virol [Internet]"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-017-0007-9","article-title":"Emerging Viral Diseases From a Vaccinology Perspective: Preparing for the Next Pandemic Review-Article","volume":"19","author":"Graham","year":"2018","journal-title":"Nat Immunol [Internet]"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus From Patients With Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01452-3","article-title":"REGN-EB3: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs [Internet]"},{"key":"B75","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.immuni.2018.06.018","article-title":"Multifunctional Pan-Ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein","volume":"49","author":"Gilchuk","year":"2018","journal-title":"Immun [Internet]"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02171-15","article-title":"Pan-Ebolavirus and Pan-Filovirus Mouse Monoclonal Antibodies: Protection Against Ebola and Sudan Viruses","volume":"90","author":"Holtsberg","year":"2016","journal-title":"J Virol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.721328\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T17:49:05Z","timestamp":1630691345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.721328\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":76,"alternative-id":["10.3389\/fimmu.2021.721328"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.721328","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,30]]},"article-number":"721328"}}